Stephen Keysar
Concepts (244)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 20 | 2026 | 563 | 2.900 |
Why?
| | Neoplastic Stem Cells | 9 | 2022 | 403 | 1.900 |
Why?
| | Carcinoma, Squamous Cell | 12 | 2022 | 628 | 1.670 |
Why?
| | Xenograft Model Antitumor Assays | 16 | 2025 | 930 | 0.790 |
Why?
| | SOXB1 Transcription Factors | 3 | 2021 | 66 | 0.670 |
Why?
| | Biomarkers, Tumor | 5 | 2021 | 1339 | 0.660 |
Why?
| | CD59 Antigens | 4 | 2009 | 20 | 0.620 |
Why?
| | ErbB Receptors | 5 | 2022 | 636 | 0.600 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2020 | 48 | 0.600 |
Why?
| | Flow Cytometry | 6 | 2025 | 1163 | 0.590 |
Why?
| | Cetuximab | 5 | 2021 | 110 | 0.570 |
Why?
| | Peptides, Cyclic | 1 | 2020 | 276 | 0.540 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2024 | 1432 | 0.530 |
Why?
| | Phosphatidylinositol 3-Kinase | 2 | 2022 | 24 | 0.530 |
Why?
| | Salivary Gland Neoplasms | 1 | 2018 | 39 | 0.530 |
Why?
| | Chromosomes, Human, Pair 11 | 5 | 2010 | 61 | 0.520 |
Why?
| | Cell Line, Tumor | 15 | 2025 | 3545 | 0.490 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2013 | 992 | 0.490 |
Why?
| | Hedgehog Proteins | 3 | 2015 | 194 | 0.470 |
Why?
| | Hyaluronan Receptors | 5 | 2020 | 105 | 0.430 |
Why?
| | Veratrum Alkaloids | 2 | 2014 | 20 | 0.410 |
Why?
| | Papillomaviridae | 4 | 2025 | 113 | 0.390 |
Why?
| | Mutagenicity Tests | 2 | 2009 | 17 | 0.370 |
Why?
| | Mice | 22 | 2025 | 18297 | 0.360 |
Why?
| | Mice, Nude | 8 | 2019 | 668 | 0.350 |
Why?
| | DNA Mutational Analysis | 2 | 2009 | 410 | 0.320 |
Why?
| | Animals | 28 | 2025 | 38107 | 0.310 |
Why?
| | Papillomavirus Infections | 3 | 2025 | 345 | 0.290 |
Why?
| | Cell Proliferation | 9 | 2019 | 2502 | 0.290 |
Why?
| | RNA, Messenger | 2 | 2016 | 2791 | 0.290 |
Why?
| | Tumor Microenvironment | 5 | 2026 | 747 | 0.290 |
Why?
| | Point Mutation | 1 | 2009 | 232 | 0.270 |
Why?
| | Mutation | 5 | 2018 | 4093 | 0.270 |
Why?
| | Antineoplastic Agents | 5 | 2016 | 2219 | 0.250 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 1998 | 0.250 |
Why?
| | Melanoma | 2 | 2025 | 765 | 0.240 |
Why?
| | Smad4 Protein | 2 | 2019 | 33 | 0.240 |
Why?
| | Tumor Cells, Cultured | 5 | 2019 | 882 | 0.220 |
Why?
| | Thymus Gland | 1 | 2025 | 310 | 0.210 |
Why?
| | Oxygen | 1 | 2010 | 997 | 0.210 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2017 | 213 | 0.210 |
Why?
| | Receptor, Notch1 | 2 | 2015 | 62 | 0.200 |
Why?
| | Immunohistochemistry | 3 | 2019 | 1712 | 0.200 |
Why?
| | Organoids | 1 | 2025 | 143 | 0.200 |
Why?
| | Signal Transduction | 9 | 2024 | 5246 | 0.190 |
Why?
| | Hematopoietic Stem Cells | 2 | 2018 | 432 | 0.190 |
Why?
| | Disease Models, Animal | 6 | 2020 | 4580 | 0.190 |
Why?
| | Immunophenotyping | 3 | 2019 | 324 | 0.190 |
Why?
| | Sulfones | 2 | 2014 | 127 | 0.190 |
Why?
| | Humans | 37 | 2026 | 146342 | 0.190 |
Why?
| | Cell Culture Techniques | 1 | 2025 | 371 | 0.190 |
Why?
| | Glycine | 2 | 2014 | 184 | 0.180 |
Why?
| | Glycolysis | 1 | 2024 | 342 | 0.180 |
Why?
| | CHO Cells | 4 | 2010 | 167 | 0.180 |
Why?
| | Cricetinae | 4 | 2010 | 296 | 0.170 |
Why?
| | Phosphatidylinositol 3-Kinases | 4 | 2022 | 384 | 0.170 |
Why?
| | Caveolin 1 | 1 | 2021 | 20 | 0.170 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 245 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2020 | 1160 | 0.160 |
Why?
| | Ethyl Methanesulfonate | 3 | 2009 | 4 | 0.160 |
Why?
| | Cricetulus | 3 | 2010 | 115 | 0.160 |
Why?
| | Precancerous Conditions | 1 | 2022 | 162 | 0.160 |
Why?
| | Heterografts | 2 | 2019 | 143 | 0.160 |
Why?
| | Peptide Chain Elongation, Translational | 1 | 2020 | 18 | 0.150 |
Why?
| | DNA Repair | 2 | 2020 | 255 | 0.150 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2020 | 141 | 0.150 |
Why?
| | Radiotherapy Dosage | 1 | 2020 | 289 | 0.150 |
Why?
| | Antigens, CD | 2 | 2016 | 560 | 0.150 |
Why?
| | Stem Cell Niche | 1 | 2019 | 57 | 0.140 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 200 | 0.140 |
Why?
| | Mouth Neoplasms | 1 | 2019 | 88 | 0.140 |
Why?
| | Neoplasm Transplantation | 2 | 2016 | 238 | 0.140 |
Why?
| | Neoplasm Proteins | 2 | 2024 | 444 | 0.140 |
Why?
| | Protein Kinase Inhibitors | 2 | 2015 | 983 | 0.140 |
Why?
| | Neoplasms | 2 | 2014 | 2954 | 0.140 |
Why?
| | Genetic Heterogeneity | 1 | 2019 | 67 | 0.140 |
Why?
| | Carcinogenesis | 2 | 2018 | 226 | 0.140 |
Why?
| | Radiotherapy | 1 | 2019 | 209 | 0.140 |
Why?
| | Chemoradiotherapy | 1 | 2020 | 238 | 0.140 |
Why?
| | Chromosome Aberrations | 1 | 2019 | 167 | 0.130 |
Why?
| | Mutagens | 2 | 2009 | 27 | 0.130 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2018 | 63 | 0.130 |
Why?
| | Radiation Tolerance | 2 | 2016 | 101 | 0.130 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2016 | 314 | 0.130 |
Why?
| | Gene Deletion | 1 | 2019 | 385 | 0.130 |
Why?
| | T-Lymphocytes | 1 | 2025 | 2012 | 0.130 |
Why?
| | DNA Damage | 1 | 2020 | 439 | 0.120 |
Why?
| | Retinal Dehydrogenase | 1 | 2016 | 27 | 0.120 |
Why?
| | Receptor, EphB4 | 1 | 2016 | 33 | 0.120 |
Why?
| | Cell Cycle | 1 | 2020 | 595 | 0.120 |
Why?
| | Cell Communication | 1 | 2018 | 327 | 0.120 |
Why?
| | Wnt Signaling Pathway | 1 | 2018 | 211 | 0.120 |
Why?
| | Corynebacterium | 1 | 2017 | 50 | 0.120 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 457 | 0.120 |
Why?
| | Corynebacterium Infections | 1 | 2017 | 43 | 0.120 |
Why?
| | Neoplasms, Experimental | 1 | 2017 | 163 | 0.120 |
Why?
| | Small Molecule Libraries | 1 | 2017 | 113 | 0.120 |
Why?
| | Proto-Oncogene Proteins | 3 | 2014 | 616 | 0.120 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2016 | 455 | 0.120 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2016 | 98 | 0.120 |
Why?
| | Spheroids, Cellular | 1 | 2016 | 81 | 0.110 |
Why?
| | Immunotherapy | 1 | 2020 | 671 | 0.110 |
Why?
| | Oncogene Proteins | 1 | 2015 | 61 | 0.110 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2015 | 54 | 0.110 |
Why?
| | Transforming Growth Factor beta2 | 1 | 2015 | 32 | 0.110 |
Why?
| | Cell Division | 1 | 2016 | 736 | 0.110 |
Why?
| | Cadherins | 1 | 2016 | 202 | 0.110 |
Why?
| | Gene Dosage | 1 | 2015 | 146 | 0.110 |
Why?
| | Recurrence | 1 | 2018 | 1133 | 0.110 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 192 | 0.100 |
Why?
| | Stromal Cells | 1 | 2014 | 123 | 0.100 |
Why?
| | Sequence Analysis, RNA | 1 | 2016 | 441 | 0.100 |
Why?
| | Cytokines | 2 | 2019 | 2081 | 0.100 |
Why?
| | Cell Line | 2 | 2009 | 2814 | 0.100 |
Why?
| | Receptor, Notch2 | 1 | 2013 | 15 | 0.100 |
Why?
| | Gonanes | 1 | 2013 | 23 | 0.100 |
Why?
| | Female | 13 | 2026 | 79499 | 0.100 |
Why?
| | Receptor Cross-Talk | 1 | 2013 | 24 | 0.100 |
Why?
| | Alphapapillomavirus | 1 | 2013 | 35 | 0.090 |
Why?
| | Sarcoma | 1 | 2015 | 209 | 0.090 |
Why?
| | ras Proteins | 1 | 2013 | 148 | 0.090 |
Why?
| | Thy-1 Antigens | 2 | 2009 | 11 | 0.090 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2018 | 704 | 0.090 |
Why?
| | Gene Silencing | 1 | 2013 | 200 | 0.090 |
Why?
| | Pyrimidines | 1 | 2015 | 532 | 0.090 |
Why?
| | Pyrazoles | 1 | 2015 | 517 | 0.080 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2015 | 893 | 0.080 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1792 | 0.080 |
Why?
| | CD24 Antigen | 1 | 2010 | 18 | 0.080 |
Why?
| | Blotting, Western | 1 | 2013 | 1177 | 0.080 |
Why?
| | Mice, Inbred NOD | 2 | 2023 | 598 | 0.080 |
Why?
| | Disease Progression | 1 | 2018 | 2867 | 0.080 |
Why?
| | Epithelial-Mesenchymal Transition | 3 | 2019 | 219 | 0.080 |
Why?
| | Dimethyl Sulfoxide | 1 | 2010 | 42 | 0.080 |
Why?
| | Free Radical Scavengers | 1 | 2010 | 81 | 0.080 |
Why?
| | Transcriptome | 1 | 2016 | 1068 | 0.070 |
Why?
| | Alkylating Agents | 1 | 2009 | 23 | 0.070 |
Why?
| | Asbestos | 1 | 2009 | 35 | 0.070 |
Why?
| | Apoptosis | 4 | 2019 | 2439 | 0.070 |
Why?
| | Gamma Rays | 1 | 2009 | 56 | 0.070 |
Why?
| | Mutagenesis | 1 | 2010 | 196 | 0.070 |
Why?
| | Cell Hypoxia | 1 | 2010 | 249 | 0.070 |
Why?
| | Clone Cells | 1 | 2009 | 259 | 0.070 |
Why?
| | Keratinocytes | 2 | 2022 | 190 | 0.070 |
Why?
| | Rabbits | 1 | 2010 | 651 | 0.070 |
Why?
| | Computational Biology | 1 | 2013 | 678 | 0.070 |
Why?
| | Prognosis | 3 | 2026 | 4351 | 0.070 |
Why?
| | Cell Cycle Proteins | 3 | 2020 | 630 | 0.070 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1195 | 0.070 |
Why?
| | Glycosylphosphatidylinositols | 1 | 2007 | 11 | 0.060 |
Why?
| | Colorectal Neoplasms | 1 | 2015 | 874 | 0.060 |
Why?
| | Transfection | 1 | 2009 | 916 | 0.060 |
Why?
| | Cell Survival | 1 | 2010 | 1105 | 0.060 |
Why?
| | Skin Neoplasms | 1 | 2013 | 806 | 0.060 |
Why?
| | Genetic Markers | 1 | 2007 | 340 | 0.060 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2025 | 23 | 0.060 |
Why?
| | Coculture Techniques | 1 | 2025 | 245 | 0.050 |
Why?
| | STAT3 Transcription Factor | 1 | 2026 | 214 | 0.050 |
Why?
| | Fanconi Anemia | 1 | 2024 | 11 | 0.050 |
Why?
| | Maximum Tolerated Dose | 2 | 2015 | 217 | 0.050 |
Why?
| | BRCA2 Protein | 1 | 2024 | 69 | 0.050 |
Why?
| | BRCA1 Protein | 1 | 2024 | 84 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2025 | 271 | 0.050 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2024 | 72 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2675 | 0.050 |
Why?
| | Neoplasm Staging | 2 | 2019 | 1488 | 0.050 |
Why?
| | RNA Interference | 2 | 2016 | 472 | 0.050 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2024 | 141 | 0.050 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2025 | 269 | 0.050 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2024 | 139 | 0.050 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2022 | 70 | 0.040 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2023 | 268 | 0.040 |
Why?
| | Time Factors | 2 | 2010 | 7109 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2026 | 11821 | 0.040 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 1 | 2020 | 22 | 0.040 |
Why?
| | Feedback, Physiological | 1 | 2020 | 79 | 0.040 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2026 | 931 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2024 | 1242 | 0.040 |
Why?
| | Male | 7 | 2026 | 73396 | 0.040 |
Why?
| | Heat-Shock Proteins | 1 | 2019 | 140 | 0.040 |
Why?
| | Hyaluronic Acid | 1 | 2020 | 227 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2018 | 165 | 0.030 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2019 | 334 | 0.030 |
Why?
| | Molecular Chaperones | 1 | 2019 | 200 | 0.030 |
Why?
| | Monocytes | 1 | 2020 | 538 | 0.030 |
Why?
| | Biomarkers | 2 | 2019 | 4340 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 429 | 0.030 |
Why?
| | Middle Aged | 4 | 2026 | 36619 | 0.030 |
Why?
| | Gene Expression | 2 | 2015 | 1463 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2016 | 33 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2018 | 504 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2024 | 1468 | 0.030 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 43 | 0.030 |
Why?
| | Aged | 3 | 2026 | 26432 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2016 | 335 | 0.030 |
Why?
| | Serrate-Jagged Proteins | 1 | 2015 | 27 | 0.030 |
Why?
| | Jagged-1 Protein | 1 | 2015 | 22 | 0.030 |
Why?
| | Tumor Burden | 1 | 2016 | 326 | 0.030 |
Why?
| | Gene Duplication | 1 | 2015 | 67 | 0.030 |
Why?
| | Lamin Type A | 1 | 2015 | 49 | 0.030 |
Why?
| | Phosphorylation | 1 | 2019 | 1724 | 0.030 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2014 | 23 | 0.030 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 36 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 750 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 2092 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2016 | 633 | 0.030 |
Why?
| | Calcium-Binding Proteins | 1 | 2015 | 221 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2026 | 8391 | 0.020 |
Why?
| | Side-Population Cells | 1 | 2013 | 6 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2015 | 778 | 0.020 |
Why?
| | alpha Catenin | 1 | 2013 | 11 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2015 | 372 | 0.020 |
Why?
| | Cell Dedifferentiation | 1 | 2013 | 31 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 447 | 0.020 |
Why?
| | Bone Marrow | 1 | 2015 | 310 | 0.020 |
Why?
| | Sequence Deletion | 1 | 2013 | 190 | 0.020 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 111 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2015 | 693 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 250 | 0.020 |
Why?
| | Adult | 3 | 2026 | 41087 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2013 | 334 | 0.020 |
Why?
| | Up-Regulation | 1 | 2014 | 841 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2018 | 3125 | 0.020 |
Why?
| | Administration, Oral | 1 | 2014 | 872 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2015 | 2022 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 823 | 0.020 |
Why?
| | Pilot Projects | 1 | 2015 | 1888 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5439 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2015 | 1130 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2134 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2026 | 17438 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2015 | 1512 | 0.020 |
Why?
| | Fusion Regulatory Protein-1 | 1 | 2007 | 3 | 0.020 |
Why?
| | Tetraspanin 24 | 1 | 2007 | 7 | 0.020 |
Why?
| | Hybrid Cells | 1 | 2007 | 47 | 0.020 |
Why?
| | MicroRNAs | 1 | 2013 | 699 | 0.020 |
Why?
| | Mitomycin | 1 | 2006 | 31 | 0.020 |
Why?
| | Transcription Factors | 1 | 2014 | 1730 | 0.010 |
Why?
| | Radiation, Ionizing | 1 | 2006 | 84 | 0.010 |
Why?
| | Cross-Linking Reagents | 1 | 2006 | 208 | 0.010 |
Why?
| | Organometallic Compounds | 1 | 2006 | 110 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2786 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 1031 | 0.010 |
Why?
| | Young Adult | 1 | 2014 | 14330 | 0.010 |
Why?
|
|
Keysar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|